Free Trial

Heck Capital Advisors LLC Acquires New Position in Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Heck Capital Advisors LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 9,933 shares of the company's stock, valued at approximately $988,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. TI Trust Inc. raised its stake in Merck & Co., Inc. by 0.6% during the fourth quarter. TI Trust Inc. now owns 19,834 shares of the company's stock worth $1,973,000 after purchasing an additional 111 shares during the period. Hengehold Capital Management LLC raised its stake in Merck & Co., Inc. by 0.3% during the fourth quarter. Hengehold Capital Management LLC now owns 39,989 shares of the company's stock worth $3,978,000 after purchasing an additional 112 shares during the period. Peterson Wealth Services raised its position in shares of Merck & Co., Inc. by 0.5% in the 4th quarter. Peterson Wealth Services now owns 21,479 shares of the company's stock worth $2,137,000 after buying an additional 113 shares during the period. Hemington Wealth Management raised its position in shares of Merck & Co., Inc. by 3.2% in the 4th quarter. Hemington Wealth Management now owns 4,050 shares of the company's stock worth $402,000 after buying an additional 125 shares during the period. Finally, Center for Financial Planning Inc. raised its position in shares of Merck & Co., Inc. by 0.9% in the 4th quarter. Center for Financial Planning Inc. now owns 14,805 shares of the company's stock worth $1,473,000 after buying an additional 125 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on MRK shares. TD Cowen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their price objective for the stock from $121.00 to $100.00 in a report on Monday, February 10th. Citigroup restated a "neutral" rating and issued a $84.00 price target (down previously from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. Deutsche Bank Aktiengesellschaft lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their price target for the company from $128.00 to $105.00 in a report on Tuesday, February 18th. Morgan Stanley cut their target price on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Finally, TD Securities downgraded shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their target price for the company from $121.00 to $100.00 in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seven have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $109.19.

Read Our Latest Research Report on MRK

Insider Buying and Selling

In related news, SVP Dalton E. Smart III sold 4,262 shares of Merck & Co., Inc. stock in a transaction on Friday, April 25th. The shares were sold at an average price of $82.76, for a total value of $352,723.12. Following the completion of the sale, the senior vice president now owns 7,778 shares in the company, valued at approximately $643,707.28. The trade was a 35.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.09% of the company's stock.

Merck & Co., Inc. Stock Down 1.8%

Shares of NYSE MRK traded down $1.42 during midday trading on Wednesday, reaching $76.17. 12,271,678 shares of the company's stock were exchanged, compared to its average volume of 12,567,486. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $134.63. The stock has a market capitalization of $191.27 billion, a PE ratio of 11.32, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The business's fifty day moving average price is $81.09 and its two-hundred day moving average price is $91.05.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company had revenue of $15.53 billion for the quarter, compared to the consensus estimate of $15.59 billion. During the same period in the previous year, the business earned $2.07 EPS. Merck & Co., Inc.'s revenue for the quarter was down 1.6% compared to the same quarter last year. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 8th. Investors of record on Monday, June 16th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, June 16th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 4.25%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 47.16%.

Merck & Co., Inc. announced that its board has authorized a stock buyback program on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines